LMAO LMF ACQUISITION OPPORTUNITIES INC

SeaStar Medical to Present at the JMP Securities Life Sciences Conference on May 16, 2023

SeaStar Medical to Present at the JMP Securities Life Sciences Conference on May 16, 2023

DENVER, May 10, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that Eric Schlorff, CEO, will present a company overview at the JMP Securities Life Sciences Conference on Tuesday, May 16, 2023 at 2:30 p.m. Eastern time. The conference is being held at the New York Hilton Midtown.

A live and archived webcast of the presentation will be posted to section of the SeaStar Medical website.

About SeaStar Medical

SeaStar Medical is a medical technology company that is redefining how extracorporeal therapies may reduce the consequences of excessive inflammation on vital organs. SeaStar Medical’s novel technologies rely on science and innovation to provide life-saving solutions to critically ill patients. The Company is developing and commercializing cell-directed extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. For more information visit or visit us on or .

Contacts:

Media

PSC Consulting

Patty Caballero

(973) 348-5055

Investors

LHA Investor Relations

Jody Cain

(310) 691-7100

# # #



EN
10/05/2023

Underlying

LMAOLMF ACQUISITION OPPORTUNITIES INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on LMF ACQUISITION OPPORTUNITIES INC

 PRESS RELEASE
Free
LMAO LMF ACQUISITION...

SeaStar Medical Reports 2023 Financial Results and Provides a Business...

SeaStar Medical Reports 2023 Financial Results and Provides a Business Update DENVER, April 17, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, reports financial results for the 12 months ended December 31, 2023 and provides a business update. “It was exceptionally exciting to receive our first FDA approval for Quelimmune™, which is now available for treating critically ill pediatri...

April 17, 2024 1 EN
 PRESS RELEASE
Free
LMAO LMF ACQUISITION...

SeaStar Medical to Present at the Noble Capital Markets’ Emerging Grow...

SeaStar Medical to Present at the Noble Capital Markets’ Emerging Growth Virtual Healthcare Equity Conference DENVER, April 11, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that management will present at the Noble Capital Markets’ Emerging Growth Virtual Healthcare Equity Conference on Thursday, April 18 at 9:30 a.m. Eastern time. The formal presentation will be followed by a hosted question-and-answer session. Investors interested in view...

April 11, 2024 1 EN
 PRESS RELEASE
Free
LMAO LMF ACQUISITION...

SeaStar Medical to Restate Financials, Sets Business Update Call for A...

SeaStar Medical to Restate Financials, Sets Business Update Call for April 17 Restatement of non-cash items is not expected to materially impact cash position or operations DENVER, March 27, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that it will restate its financial statements for the fiscal year ended December 31, 2022 and for the interim periods ended March 31, 2023, June 30, 2023 and September 30, 2023. The restatement will imp...

March 27, 2024 1 EN
 PRESS RELEASE
Free
LMAO LMF ACQUISITION...

SeaStar Medical Provides Updates on Enrollment of Adult Pivotal Clinic...

SeaStar Medical Provides Updates on Enrollment of Adult Pivotal Clinical Study and Commercial Launch of Quelimmune, FDA-Approved in Pediatric Patients Company plans to hold a business update conference call in April DENVER, March 12, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: ICU), a commercial stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, provides updates on the acute kidney injury (AKI) programs it is developing with its patented, first-to-market, cell-directed Selective Cytopheretic Device (SCD) extracorporea...

March 12, 2024 1 EN
 PRESS RELEASE
Free
LMAO LMF ACQUISITION...

SeaStar Medical-Sponsored Symposium Featuring Experts Discussing Pedia...

SeaStar Medical-Sponsored Symposium Featuring Experts Discussing Pediatric Acute Kidney Injury and the Selective Cytopheretic Device to be Webcast Live at AKI & CRRT 2024 March 13 webcast showcasing Quelimmune™ scientific background and clinical data for pediatric AKI due to sepsis or a septic condition will be available on DENVER, March 11, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces its sponsorship of an Industry Symposium titled “New Therapies in Pediatr...

March 11, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch